MedDataX Logo

Relation Between Serum IGF-1 & BMI In Acne Vulgaris

NCT ID: NCT05301569

Last Updated: 2023-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2024-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

cross-sectional study in which participants will be recruited at dermatology \& Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists \& obtaining an informed consent

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Evaluation of Serum Level of Insulin Like Growth Factor 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged from 15 to 45 years old suffering from acne vulgaris.
2. Both sexes.

Exclusion Criteria

1. Insulin resistance and diabetic patients
2. Females with polycystic ovarian syndrome
3. Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study.
4. Other causes of acne or acneform eruption as steroid-induced
Minimum Eligible Age

15 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rania Sallam Mohamed Taha

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rania Sallam

Cairo, Qalubya, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rania Sallam

Role: CONTACT

Phone: 113567939

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rania Sallam

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IGF-1 in AV

Identifier Type: -

Identifier Source: org_study_id